The knowledge of D variants in patients and donors is important because anti-D alloimmunization can occur in some but not all individuals who express a variant RHD allele. Serologic distinction of RhD discrepancies is not always straightforward, which makes molecular analysis highly desirable. 
INTRODUCTION
The D antigen is very immunogenic and most important in the Rh blood group system, because D− individuals can be easily immunized (1, 2) . Anti-D is clinically significant as it causes hemolytic transfusion reactions and hemolytic disease of the fetus and newborn (HDFN) (2) . Besides D+ and D− phenotypes, there is a plethora of D variants characterized as weak D, partial D, and deletion (DEL) and in recent years an increasing number of altered RHD alleles have been reported (RhesusBase) (3) . The molecular mechanisms responsible for D variants predominantly include nucleotide changes in RHD, resulting in amino acid substitutions in the RhD protein, and genetic recombination giving rise to a hybrid RhD protein (4) (5) (6) .
Serologic tests cannot distinguish between partial D and weak D types but can detect variants with weakened or altered expression, and therefore discrepancies in the serologic routine analysis should be investigated by molecular methods (7) .
Weak D types 1-3 are the most frequent variants detected by serology, but frequencies vary in different populations (8) (9) (10) (11) (12) . The populations of African admixture, such as the Brazilian population, can present a high variety of RHD alleles and therefore information on the prevalence of different variants can impact the typing and transfusion strategy.
Individuals with DEL and partial D variant alleles have the potential to form anti-D, whereas common weak D types 1-3 do not form anti-D (13) (14) (15) . It has been recommended that weak D patients with the most common types may receive D+ red blood cells (RBCs) to conserve stocks of D− RBCs, and partial D patients should be given D− RBCs (8, 16) . The identification of D variants is important for selection of blood products and prevention of anti-D-related HDFN (2) .
In the past years, we introduced in our D typing routine the use of immunoglobulin G (IgG), immunoglobulin M (IgM), and blend anti-D reagents in tube and gel, and noted a high frequency of RhD discrepancies among patients and blood donor samples. Here, we describe the serology and molecular analyses performed to identify D variants with discrepant results of D typing in order to determine the frequencies of D variants in this Brazilian population and to avoid the unnecessary use of D− blood in those patients who are not at the risk of anti-D alloimmunization. We also evaluated, retrospectively, whether patients molecularly characterized as D variant developed alloanti-D. 
MATERIALS AND METHODS

Samples
Molecular Analyses
DNA was extracted from whole blood using the QIAmp DNA Blood Mini-Kit (Qiagen, Valencia, CA), according to the manufacture's recommendations. Molecular tests performed on all 223 discrepant samples included PCR-SSP that detects the common weak D types (14) and a multiplex PCR that detects the RHD gene hybrid alleles (17) for all samples; RHD BeadChip TM (Bioarray Solutions, Immucor, NJ) was used for 55 samples. However, six samples could not be assigned an RHD allele and were subjected to direct automated sequencing of RHD using RHD-specific primers as previously reported (18) .
RESULTS
Molecular Analyses
The molecular analyses confirmed the presence of D variants in all samples with discrepant results in serology. 
Serology
The reactivity of monoclonal anti-D reagents and methods used in this process varied among the samples with different D variants, but presented a consistent pattern among the same types of variants. Table 2 
DISCUSSION
RHD genotyping is recommended when discordant RhD typing results are encountered and/or serologic weak D reactivity is observed (7, 8) . The identification and differentiation of D variants can avoid the unnecessary use of RhD-negative RBCs in patients who are not at risk of alloimmunization, and therefore could have an important impact on the transfusion strategies in countries such as Brazil, where the prevalence of D− phenotypes ranges from 5% to 12%.
In this study, we used molecular assays to analyze samples of patients and donors in São Paulo, Brazil, with discrepancies in serologic RhD typing, and 12 variant RHD alleles were identified. Our molecular approach used for identifying the Brazilian samples with RhD antigen discrepancies recognized RHD variant alleles in all the investigated samples, reinforcing the need to set up a strategy for serologic discrepancies identification and resolution.
RhD antigen serologic discrepancies have been associated with specific partial D and weak D types generally associated with ethnicity (10) (11) (12) (13) (14) (15) . Most studies on frequencies of RHD alleles were performed in Central Europe and show that approximately 95% of Caucasians with serologic weak D phenotype have weak D types 1-3 (14) . The prevalence of weak D types 1 through 3, which we observed in this population of patients and donors with weak D expression, is much lower (approximately 63%) and we observe a higher prevalence (15%) of weak D type 4.0. These data differ from studies performed in Caucasians but are consistent with another study performed in Brazilians (19) . For the partial D, we observed a higher prevalence of DAR, DIVa, and DVI, reinforcing that the prevalence of D variants may be associated with the ethnic background of a population. Weak D and partial D, and the associated CE haplotypes found in this study were consistent with the haplotypes found in other studies (4) . It is well established that transfusion recipients with the most common weak D types 1-3 are not at risk of forming alloanti-D when exposed to conventional RhD-positive RBCs (7, 9) and, according to our results, 83 of 129 (64%) patients could be managed safely as RhD-positive. Although there are few reports of anti-D in patients with weak D type 4.0 (8, 9, 20) , it is still recommended to manage this weak D type as RhD-negative (16) .
In In conclusion, this study gives insight into the diversity, frequencies, and clinical relevance of the variant RHD alleles in Brazilians with discrepancies in RhD typing. Moreover, here we show that although weak D types 1 through 3 are most common in our population, their prevalence is much lower than the types found in Europeans. These findings may contribute to the development of D phenotyping and genotyping strategies in this population for more precise clinical decision making in transfusion medicine and obstetric practice.
